series-a
Stage
2021
Founded
1
Investors
About
Haystack Oncology develops and provides a tumor-informed minimal residual disease (MRD) test called Haystack MRD that detects circulating tumor DNA in blood to assist clinicians and biopharma in detecting residual or recurring solid tumor cancers with high accuracy.
Explore Haystack Oncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.